Drug Profile
Research programme: AMPA receptor modulators - OLAS Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator OLAS Pharmaceuticals
- Class
- Mechanism of Action AMPA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Endocrine disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Endocrine-disorders in USA
- 25 Sep 2007 Preclinical trials in Endocrine disorders in USA (unspecified route)